Transcriptomic Mapping of Neurotoxicity Pathways in the Rat Brain in Response to Intraventricular Polymyxin B.
Jing LuYan ZhuHelena C ParkingtonMaytham HusseinJinxin ZhaoPhillip BergenDavid RuddMary A DeaneSara OberrauchLinda Cornthwaite-DuncanRafah AllobawiRajnikant SharmaGauri RaoJian LiXukai JiangPublished in: Molecular neurobiology (2022)
Intraventricular or intrathecal administration of polymyxins are increasingly used to treat multidrug-resistant (MDR) Gram-negative bacteria caused infections in the central nervous system (CNS). However, our limited knowledge of the mechanisms underpinning polymyxin-induced neurotoxicity significantly hinders the development of safe and efficacious polymyxin dosing regimens. To this end, we conducted transcriptomic analyses of the rat brain and spinal cord 1 h following intracerebroventricular administration of polymyxin B into rat lateral ventricle at a clinically relevant dose (0.5 mg/kg). Following the treatment, 66 differentially expressed genes (DEGs) were identified in the brain transcriptome while none for the spinal cord (FDR ≤ 0.05, fold-change ≥ 1.5). DEGs were enriched in signaling pathways associated with hormones and neurotransmitters, including dopamine and (nor)epinephrine. Notably, the expression levels of Slc6a3 and Gabra6 were decreased by 20-fold and 4.3-fold, respectively, likely resulting in major perturbations of dopamine and γ-aminobutyric acid signaling in the brain. Mass spectrometry imaging of brain sections revealed a distinct pattern of polymyxin B distribution with the majority accumulating in the injection-side lateral ventricle and subsequently into third and fourth ventricles. Polymyxin B was not detectable in the left lateral ventricle or brain tissue. Electrophysiological measurements on primary cultured rat neurons revealed a large inward current and significant membrane leakage following polymyxin B treatment. Our work demonstrates, for the first time, the key CNS signaling pathways associated with polymyxin neurotoxicity. This mechanistic insight combined with pharmacokinetic/pharmacodynamic dosing strategies will help guide the design of safe and effective intraventricular/intrathecal polymyxin treatment regimens for CNS infections caused by MDR Gram-negative pathogens.
Keyphrases
- gram negative
- multidrug resistant
- drug resistant
- spinal cord
- acinetobacter baumannii
- single cell
- klebsiella pneumoniae
- mass spectrometry
- white matter
- signaling pathway
- pulmonary artery
- mitral valve
- resting state
- spinal cord injury
- high resolution
- blood brain barrier
- rna seq
- pulmonary hypertension
- healthcare
- oxidative stress
- minimally invasive
- uric acid
- neuropathic pain
- heart failure
- epithelial mesenchymal transition
- pi k akt
- brain injury
- long non coding rna
- cystic fibrosis
- poor prognosis
- multiple sclerosis
- functional connectivity
- escherichia coli
- combination therapy
- cell proliferation
- photodynamic therapy
- capillary electrophoresis
- left ventricular
- ms ms
- high performance liquid chromatography
- induced apoptosis
- coronary artery
- liquid chromatography
- replacement therapy